A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment
Pharmaceuticals · 15.11.2023 · 16 (11) · 1614
DOI: 10.3390/ph16111614 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 15.11.2023. Verfasst von Serena Tseng und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Science and Technology, Taiwan, Ministry of Science and Technology, Taiwan, Kaohsiung Medical University Hospital.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is the second most common hematologic malignancy in children. The incidence of childhood AML is much lower than acute lymphoblastic leukemia (ALL), which makes childhood AML a rare disease in children. The role of genetic abnormalities in AML classification, management, and prognosis prediction is much more important than before. Disease classifications and risk group classifications, such as the WHO classification, the international consensus classification (ICC), and the European LeukemiaNet (ELN) classification, were revised in 2022. The application of the new information in childhood AML will be upcoming in the next few years. The frequency of each genetic abnormality in adult and childhood AML is different; therefore, in this review, we emphasize well-known genetic subtypes in childhood AML, including core-binding factor AML (CBF AML), KMT2Ar (KMT2A/11q23 rearrangement) AML, normal karyotype AML with somatic mutations, unbalanced cytogenetic abnormalities AML, NUP98 11p15/NUP09 rearrangement AML, and acute promyelocytic leukemia (APL). Current risk group classification, the management algorithm in childhood AML, and novel treatment modalities such as targeted therapy, immune therapy, and chimeric antigen receptor (CAR) T-cell therapy are reviewed. Finally, the indications of hematopoietic stem cell transplantation (HSCT) in AML are discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
Förderung
- The Ministry of Science and Technology, Taiwan
- Ministry of Science and Technology, Taiwan
- Kaohsiung Medical University Hospital
Zitieren
APA
Tseng, S., Lee, M. E., & Lin, P. C. (2023). A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment. Pharmaceuticals, 16(11), 1614. https://doi.org/10.3390/ph16111614
Vancouver
Tseng S, Lee ME, Lin PC. A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment. Pharmaceuticals. 2023;16(11):1614. doi:10.3390/ph16111614
BibTeX
@article{Tseng2023,
author = {Tseng, Serena and Lee, Mu-En and Lin, Pei-Chin},
title = {A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {11},
pages = {1614},
doi = {10.3390/ph16111614}
}
EUVIMED